Ulmer J B, Deck R R, DeWitt C M, Friedman A, Donnelly J J, Liu M A
Department of Virus and Cell Biology, Merck Research Laboratories, West Point, PA 19486.
Vaccine. 1994 Dec;12(16):1541-4. doi: 10.1016/0264-410x(94)90081-7.
Dose-response relationships were investigated between dose of influenza virus haemagglutinin (HA) or nucleoprotein (NP) DNA vaccines, and immunogenicity and protective efficacy based on humoral and cellular immunity. In mice, intramuscular (i.m.) injection of HA or NP DNA, at doses of 100 ng to 1 microgram, was found to generate haemagglutination inhibiting (HI) antibodies and cytotoxic T-lymphocytes, respectively, and provide protection in influenza virus challenge models. A direct correlation between the amount of DNA injected and the level of HI antibody was observed. In non-human primates, high-titre neutralizing antibodies were induced in animals vaccinated with as little as 10 micrograms of HA DNA. These results indicate that low doses of DNA administered by i.m. injection provide protective efficacy against influenza.
研究了流感病毒血凝素(HA)或核蛋白(NP)DNA疫苗剂量与基于体液免疫和细胞免疫的免疫原性及保护效力之间的剂量反应关系。在小鼠中,肌肉注射100 ng至1微克剂量的HA或NP DNA,分别产生了血凝抑制(HI)抗体和细胞毒性T淋巴细胞,并在流感病毒攻击模型中提供了保护。观察到注射的DNA量与HI抗体水平之间存在直接相关性。在非人类灵长类动物中,用低至10微克的HA DNA接种疫苗的动物诱导产生了高滴度中和抗体。这些结果表明,通过肌肉注射给予低剂量DNA可提供针对流感的保护效力。